H.C. Wainwright raised the firm’s price target on Y-mAbs Therapeutics to $22 from $21 and keeps a Buy rating on the shares following the Q4 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on YMAB:
- Biotech Alert: Searches spiking for these stocks today
- Y-mAbs Therapeutics price target raised to $26 from $16 at BMO Capital
- Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
- Y-mAbs Therapeutics appoints Tagliaferri to board of directors
- Y-mAbs Therapeutics price target raised to $26 from $22 at Canaccord
